Scholar Rock says FDA approved ISEMBYLD, corrects safety-study statement from investor call
Scholar Rock disclosed that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years and older receiving an SMN2-targeted treatment. The company also corrected management's statement during the September 14, 2026 investor call that the FDA required no post-marketing safety commitments, saying the FDA does require a pregnancy safety study and fracture alert reports.
Key points
- FDA approved ISEMBYLD for SMA patients aged 2 and older currently on an SMN2-targeted treatment
- FDA requires a post-marketing pregnancy safety study covering pregnancy complications and birth outcomes
- FDA requested that all serious and non-serious fracture cases be submitted as 15-day alert reports
- Correction was made to statements made in error during the September 14, 2026 investor call
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.